Risk factor
Low price volatility
Profitability factor
Good margins and returns
About
Hisamitsu Pharmaceutical Co., Inc. is a Japanese enterprise specializing in the development, manufacturing, and distribution of a wide array of healthcare solutions. Its extensive product catalog includes pharmaceuticals, medical devices, quasi-drugs, and cosmetics, catering to markets in Japan, the United States, and Asia. The company is particularly recognized for its comprehensive range of external pain relief medications, featuring popular brands such as SALONPAS, NOBINOBI, SALONSIP, AIR, and FEITAS. Additionally, Hisamitsu offers various transdermal patches for pain and inflammation, including MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Beyond pain management, its portfolio addresses other conditions with products like BUTENALOCK for athlete's foot and ALLEGRA FX for allergy and sinus symptoms. Specialized therapeutic patches for female hormone regulation, asthma, overactive bladders, and the HFT-290 patch for cancer pain further highlight its diverse pharmaceutical offerings. Founded in Tosu, Japan, in 1847, Hisamitsu Pharmaceutical boasts a rich history in the industry.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBIT
Target Price
The average target price of 4530.T is 4300 and suggests 29% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to d